Literature DB >> 7599289

Primary non-Hodgkin's lymphoma of the vagina. Case report and review of the literature.

H G Höffkes1, A Schumann, M Uppenkamp, C Teschendorf, A E Schindler, R Parwaresch, G Brittinger.   

Abstract

The genital tract as primary site of malignant non-Hodgkin's lymphoma in women is extremely rare, whereas secondary involvement in advanced disease is found in about 40% of cases. In this report a patient is presented who had a primary vaginal non-Hodgkin's lymphoma of the centroblastic type according to the Kiel classification, with an excellent response to cytotoxic chemotherapy (CHOP) and event-free disease for 3 years. A review of the literature shows that favorable prognosis of localized disease seems to be a common experience. Primary involvement of the vagina can be successfully treated by pelvic irradiation, but in young women cytotoxic chemotherapy should be considered to preserve fertility.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7599289     DOI: 10.1007/BF01784047

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  23 in total

1.  Detection of a monocyte/macrophage differentiation antigen in routinely processed paraffin-embedded tissues by monoclonal antibody Ki-M1P.

Authors:  H J Radzun; M L Hansmann; H J Heidebrecht; S Bödewadt-Radzun; H H Wacker; H Kreipe; H Lumbeck; C Hernandez; C Kuhn; M R Parwaresch
Journal:  Lab Invest       Date:  1991-09       Impact factor: 5.662

2.  Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases.

Authors:  S E Jones; Z Fuks; M Bull; M E Kadin; R F Dorfman; H S Kaplan; S A Rosenberg; H Kim
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

3.  Primary malignant reticuloendothelial disease involving the vagina, cervix, and corpus uteri.

Authors:  I Chorlton; R F Karnei; F M King; H J Norris
Journal:  Obstet Gynecol       Date:  1974-11       Impact factor: 7.661

4.  Utilization of monoclonal antibody L26 in the identification and confirmation of B-cell lymphomas. A sensitive and specific marker applicable to formalin-and B5-fixed, paraffin-embedded tissues.

Authors:  R W Cartun; F B Coles; W T Pastuszak
Journal:  Am J Pathol       Date:  1987-12       Impact factor: 4.307

5.  Ki-B5: a monoclonal antibody unrelated to CD45 recognizes normal and neoplastic human B cells in routine paraffin sections.

Authors:  M L Hansmann; H H Wacker; J Gralla; H Lumbeck; M Kossmahl; H J Heidebrecht; H J Radzun; M R Parwaresch
Journal:  Blood       Date:  1991-02-15       Impact factor: 22.113

Review 6.  Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group.

Authors:  G Brittinger; H Bartels; H Common; E Dühmke; H H Fülle; U Gunzer; T Gyenes; R Heinz; E König; P Meusers
Journal:  Hematol Oncol       Date:  1984 Jul-Sep       Impact factor: 5.271

7.  Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.

Authors:  E M McKelvey; J A Gottlieb; H E Wilson; A Haut; R W Talley; R Stephens; M Lane; J F Gamble; S E Jones; P N Grozea; J Gutterman; C Coltman; T E Moon
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

8.  Malignant lymphoma of the uterus. Report of seven cases with immunohistochemical study.

Authors:  K Aozasa; K Saeki; M Ohsawa; K Horiuchi; K Mishima; M Tsujimoto
Journal:  Cancer       Date:  1993-09-15       Impact factor: 6.860

Review 9.  Stage IE primary malignant lymphomas of the uterine cervix.

Authors:  H G Muntz; J A Ferry; D Flynn; A F Fuller; H M Tarraza
Journal:  Cancer       Date:  1991-11-01       Impact factor: 6.860

10.  [Malignant lymphomas of the vulva and vagina].

Authors:  K Chalubinski; G Breitenecker; G Tatra
Journal:  Geburtshilfe Frauenheilkd       Date:  1992-10       Impact factor: 2.915

View more
  1 in total

1.  Genital ulceration revealing a primary cutaneous anaplastic lymphoma.

Authors:  B Cribier; D Lipsker; E Grosshans; C Duhem; C Capesius; M Dicato
Journal:  Genitourin Med       Date:  1997-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.